Shares of NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report) traded up 5.5% during mid-day trading on Wednesday . The company traded as high as $4.25 and last traded at $4.23. 72,045 shares changed hands during mid-day trading, an increase of 204% from the average daily volume of 23,728 shares. The stock had previously closed at $4.01.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e)” rating on shares of NLS Pharmaceutics in a report on Monday, June 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, NLS Pharmaceutics has a consensus rating of “Sell”.
View Our Latest Research Report on NCEL
NLS Pharmaceutics Stock Performance
Insider Buying and Selling
In other NLS Pharmaceutics news, Director Olivier Samuel acquired 81,818 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $2.75 per share, with a total value of $224,999.50. Following the completion of the transaction, the director owned 81,818 shares in the company, valued at $224,999.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michel Revel bought 54,545 shares of NLS Pharmaceutics stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the purchase, the director directly owned 957,530 shares of the company’s stock, valued at approximately $2,633,207.50. The trade was a 6.04% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 16.40% of the company’s stock.
About NLS Pharmaceutics
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
Read More
- Five stocks we like better than NLS Pharmaceutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
